adult onset still disease 1
Download
Report
Transcript adult onset still disease 1
Dr. Müge Bıçakçıgil Kalaycı
ADULT ONSET STILL DISEASE
Multi-system inflammatory disease
begins with a sore throat
may develop days to weeks before
the typical quotidian fever
Rash
Joint pains
ETIOLOGY
no etiologic factor has been identified
Infectious??
prodromal sore throat
fever
Possible mechanism;
- viral agent initiates a cascade of the immunological
events resulting in the characteristic clinical syndrome
of AOSD.
Implicated organisms in AOSD
-Rubella
-Mycoplasma
-Ebstein Barr
-Borelia burgdoferi
-Staphylococcus
-Cytomegalovirus
-Parvovirus
-Mumps
-Yersinia enterocolitica
-Parainfluenza
Brucela abortus
Clinical Features
Common Clinical Features
*Fever of at least 39ºC lasting one week or longer
*Arthralgias or arthritis lasting two weeks or longer
*Characteristic rash which is a macular or
maculopapular, nonpruritic, salmon-pink
eruption usually apparent over the trunk or
extremities during febrile episodes
* Leukocytosis (10,000/µL or greater) with 80
percent or more granulocytes
* Sore throat
* Recent development of significant lymph node swelling
* Hepatomegaly or splenomegaly
*Abnormal liver function studies, particularly
aminotransferases and lactate dehydrogenase
*Negative tests for antinuclear antibody and rheumatoid
factor
FEVER
Quotidian or "double-quotidian" with a brief peak
in the late afternoon or early evening.
Temperature swings can be dramatic, with changes
of 4ºC occurring in four hours.
Approximately 20 percent of cases, fever persists
between spikes.
Over 99 % of patients manifest with fever > 39 0 C
FEVER
The febrile paroxysms are cyclic and tend to recur every 24 or
sometimes every 12 hours. Characteristically very high in the
evening, returning to normal by morning.
Paroxysms are heralded by shaking chills, followed by 2-4
hours of high fever (> 104°F), and ending with defervescence
and drenching sweats
RASH
Still's rash is seen in 86% of patients
Periodic appearance and location
Appears during febrile attacks and may last for several
hours
It is typically salmon-colored (infrequently
erythematous), maculopapular and may be confluent
or show areas of central clearing.
Trunk, neck, extremity( extensor surface)
RASH
Usually the face, palms, and soles are spared.
Dermatographism: is an exaggerated cutaneous
urticarial response to cutaneous stimuli (ie, the
scratch test).
Rash is typically nonpruritic.
Articular Manifestations
Arthralgias dominate the early clinical picture
During the first 6 mos. the onset of polyarthritis is
expected in > 90% of patients and may involve large and
small articulations
Myalgias
Affected joints: the knees, wrists, ankle, elbow, shoulder,
PlPs, DlPs, TMJ and cervical spine.
Bony ankylosis of carpal, carpometacarpal. Intertarsal
joints
Erosive and destructive polyarthritis, especially in those
with a chronic polyarticular course
Reticuloendothelial Disease
Splenomegaly
Very common early in the disease and reflects tissue infiltration with inflammatory
cells and heightened immunologic activity within the reticuloendothelial system (RES).
Palpable or radiographic demonstration of splenomegaly is seen in 42% of individuals
Hepatomegly
40% of patients are found to have hepatomegaly
70% demonstrate abnormalities of hepatic enzymes at some time during their illness
Lymphadenopathy
65% of AOSD patients.
Generalized mild to moderate nodal enlargement of
nontender lymph nodes located in the cervical, axillary,
epitrochlear, or inguinal regions.
Mesenteric, para-aortic and hilar nodes may be discovered
during diagnostic imaging
SEROSITIS
Pleuritis (40%)
Pleural effusions are usually bilateral, seldom large enough
to be symptomatic, and rarely produce pleural thickening.
Thoracentesis often yields bloody, exudative effusions with
white blood cell counts ranging from 3-20 x 103/mm3 with a
polymorphonuclear predominance.
Pneumonitis
Pneumonitis is found in over 20% of patients
These individuals often appear septic with complaints of
fever, dry cough, dyspnea and are found to have pulmonary
infiltrates that are unresponsive to anti-infective therapy
Infiltrates tend to be bilateral more commonly than
unilateral, alveolar or interstitial in pattern and responds
well to anti-inflammatory therapy with steroids
Laboratory
Investigations
Absence of antinuclear antibodies
Elevated serum amyloid A
Absence of rheumatoid factor,
Thrombocytosis
Elevated ESR and C-reactive protein
Elevated serum ferritin and
glycosylated ferritin
Neutrophilic leukocytosis
Elevations the hepatic enzymes
Hypoalbuminemia
Leukocytosis
Leukocytes counts generally range between 12,500-40,000 cells/mm3,
with the highest recorded to be 69,000
ESR
90% of AOSD patients have an ESR > 50 mm/hr and 50% have and
ESR > 90 mm/hr.
Hyperferritinemia
It has been suggested that extreme elevations of the
acute phase reactant, ferritin, may be of diagnostic value
in assessing patients with AOSD
Hyperferritinemia with values between 4000 30,000
mg/ml have often been reported in association with the
onset and/or flare of disease activity
Levels as high as 250,000 mg/ml have been reported
AOSD.
Diagnosis
Diagnosis
Still disease lacks serologic test or histopathology and
thus, remains a clinical
diagnosis of exclusion.
AOSD is now being considered earlier in the course of
evaluation of patients with fever, dermatitis and
arthritis.
Diagnostic steps should include a comprehensive,
noninvasive workup, documentation of fever pattern
Yamaguchi et al 1992
AOSD Total of > 5 criteria (including 2 major)
Major Criteria
Fever > 39°C
Arthralgia > 2 wks.
Still's rash
Neutrophilic leukocytosis
Minor Criteria
Sore throat
LN or splenomegaly
Liver dysfunction
Negative RF & ANA
specificities greater than 92%, the sensitivity of Yamaguchi
(96%)
Treatment
Treatment
NSAIDS or Aspirin
Mild disease with no life- threatening visceral involvement
20-25 % respond (good prognosis group with mild disease
activity)
Aspirin or an NSAID should be continued for one to three
months following disease remission.
GLUCOCORTICOSTEROIDS
Patients with very high fever,
Joint involvement that is disabling
Potentially life-threatening visceral involvement
(myocarditis)
Starting dose of 0.5 to 1.0 mg/kg per day PO
Immunomodulating drugs
There are no controlled trials assessing the efficacy of any
of the immunomodulating drugs in ASD
* Intramuscular gold salts
* Hydroxychloroquine,
* Azathioprine,
* Cyclophosphamide,
* Cyclosporine,
* Sulfasalazine,
* Methotraxate
* Intravenous immune globulin,
* Anti-TNF-alpha agents